Treatment Options for Chemotherapy-Induced Nausea and Vomiting

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00024669-200302010-00002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Delayed emesis: incidence, pattern, prognostic factors and optimal treatment

  2002cited by this paper
• Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.

  2002cited by this paper
• A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients

  2002cited by this paper
• Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.

  2001cited by this paper
• Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret.

  2001cited by this paper
• Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

  2001cited by this paper
• Neurokinin(1) receptor antagonists as potential antidepressants.

  2001cited by this paper
• Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration

  2001cited by this paper
• A novel tachykinin NK2 receptor antagonist prevents motility‐stimulating effects of neurokinin A in small intestine

  2001cited by this paper
• Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

  2001cited by this paper
• Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.

  2001cited by this paper
• Expression of tachykinin NK2 receptor mRNA in human brain.

  2001cited by this paper
• The broad‐spectrum anti‐emetic activity of AS‐8112, a novel dopamine D2, D3 and 5‐HT3 receptors antagonist

  2001cited by this paper
• Central neurocircuitry associated with emesis.

  2001cited by this paper
• Behavioral intervention for cancer treatment side effects.

  2001cited by this paper
• Universities and tobacco money

  2001cited by this paper
• Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.

  2001cited by this paper
• Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

  2001cited by this paper
• Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

  2001cited by this paper
• Amélioration du contrôle des nausées et vomissements lors d’une chimiothérapie modérément émétisante, par l’association ondansétron méthylprednisolone etlorazépam, chez des patients en échec d’une association antiémétique antérieure

  2000cited by this paper
• The endocannabinoid system as a target for therapeutic drugs.

  2000cited by this paper
• Substance P in the dorsal motor nucleus of the vagus evokes gastric motor inhibition via neurokinin 1 receptor in rat.

  2000cited by this paper
• Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.

  2000cited by this paper
• Tachykinins in regulation of gastric motility and secretion

  2000cited by this paper
• Economics and health-related quality of life in antiemetic therapy: recommendations for trial design.

  2000cited by this paper
• Advances in use of the 5-HT3 receptor antagonists

  2000cited by this paper
• Droperidol and 5‐HT3‐receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting

  2000cited by this paper
• Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.

  2000cited by this paper
• Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting

  2000cited by this paper
• Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.

  2000cited by this paper
• The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis.

  2000cited by this paper
• Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew).

  1999cited by this paper
• Stroking human jejunal mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT4receptors.

  1999cited by this paper
• Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy.

  1999cited by this paper
• Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.

  1999cited by this paper
• Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

  1999cited by this paper
• Novel Approaches to the Treatment of Nausea and Vomiting

  1999cited by this paper
• Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study.

  1999cited by this paper
• Oral cisapride for the control of delayed vomiting following high-dose cisplatin

  1999cited by this paper
• Noxious stimulation of emesis.

  1999cited by this paper
• Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.

  1999cited by this paper
• Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

  1999cited by this paper
• The effects of cannabinoids on the brain.

  1999cited by this paper
• Serotonin receptor physiology: relation to emesis.

  1999cited by this paper
• Does Dexamethasone Enhance the Efficacy of Alizapride in Cis-Platinum-Induced Delayed Vomiting and Nausea?

  1998cited by this paper
• Immunocytochemical distribution of neurokinin 1 receptor in rat dorsal vagal complex.

  1998cited by this paper
• 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting

  1998cited by this paper
• Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.

  1998cited by this paper
• Proposal for classifying the acute emetogenicity of cancer chemotherapy.

  1997cited by this paper
• An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.

  1997cited by this paper
• Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide.

  1997cited by this paper
• Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea

  1997cited by this paper
• Multiple serotonin receptors: too many, not enough, or just the right number?

  1997cited by this paper
• Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.

  1997cited by this paper
• Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis.

  1997cited by this paper
• Tachykinins Influence Interdigestive Rhythm and Contractile Strength of Human Small Intestine

  1997cited by this paper
• Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets.

  1997cited by this paper
• Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting.

  1997cited by this paper
• Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana

  1997cited by this paper
• Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.

  1996cited by this paper
• Models, mechanisms and management of anticipatory nausea and emesis.

  1996cited by this paper
• Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.

  1996cited by this paper
• Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy.

  1996cited by this paper
• Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.

  1996cited by this paper
• Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms

  1996cited by this paper
• On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

  1996cited by this paper
• Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret.

  1996cited by this paper
• 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.

  1996cited by this paper
• Treatment of cisplatin‐related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study

  1996cited by this paper
• Blockade of motion‐ and cisplatin‐induced emesis by a 5‐HT2 receptor agonist in Suncus murinus

  1995cited by this paper
• Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin: A Prospective Randomized Trial

  1995cited by this paper
• Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis.

  1995cited by this paper
• Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

  1995cited by this paper
• Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus.

  1994cited by this paper
• Lorazepam‐Enhancement of the Antiemetic Efficacy of Dexamethasone and Promethazine: A Placebo‐Controlled Study

  1994cited by this paper
• A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin

  1994cited by this paper
• A Randomized Double‐Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin‐Based Chemotherapy

  1994cited by this paper
• Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.

  1994cited by this paper
• Possible involvement of peripheral 5-HT4 receptors in copper sulfate-induced vomiting in dogs.

  1994cited by this paper
• Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.

  1994cited by this paper
• Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone

  1993cited by this paper
• Antiemetic Efficacy of Alprazolam in the Combination of Metoclopramide Plus Methylprednisolone: Double‐Blind Randomized Crossover Study in Patients with Cisplatin‐Induced Emesis

  1993cited by this paper
• Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.

  1992cited by this paper
• The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.

  1992cited by this paper
• The use of ondansetron in patients receiving multiple-day cisplatin regimens.

  1992cited by this paper
• Cisapride: a new class of prokinetic agent. The ACG Committee on FDA-related matters. American College of Gastroenterology.

  1991cited by this paper
• Anticipatory nausea development in cancer patients: replication and extension of a learning model.

  1991cited by this paper
• General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride.

  1991cited by this paper
• The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.

  1991cited by this paper
• Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

  1991cited by this paper
• Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.

  1991cited by this paper
• Predictive Factors of Delayed Emesis in Cisplatin‐Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone: A Randomized Single‐Blind Study

  1991cited by this paper
• A randomized, double‐blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high‐dose cisplatin

  1990cited by this paper
• Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species.

  1989cited by this paper
• Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.

  1989cited by this paper
• The 5-HT4 receptor: naughty, but nice.

  1989cited by this paper
• Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

  1989cited by this paper
• Chemotherapy‐related nausea and vomiting: Etiology and management

  1989cited by this paper
• Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides.

  1988cited by this paper
• Vagal afferent discharge from gastric mechanoreceptors during contraction and relaxation of the ferret corpus.

  1987cited by this paper

• A Pharmaco-Cybernetics Approach to Patient Safety: Identifying Adverse Drug Reactions through Unsupervised Machine Learning

  2014cites this paper
• Impact of cancer‐related fatigue on chemotherapy‐induced nausea and vomiting in Asian cancer patients

  2013cites this paper
• Management of chemotherapy-induced nausea and vomiting: A pilot randomised controlled trial using Nevasic audio programme.

  2013cites this paper
• Aprepitant

  2012cites this paper
• Computational Prediction of State Anxiety in Asian Patients With Cancer Susceptible to Chemotherapy-Induced Nausea and Vomiting

  2012cites this paper
• Aprepitant

  2012influential citation
• Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting

  2012cites this paper
• Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

  2009cites this paper
• Palonosetron

  2009cites this paper
• Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

  2006cites this paper
• Antiemetic efficacy of the neurokinin‐1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high‐dose cisplatin

  2005cites this paper
• Treatment Options for Chemotherapy-Induced Nausea and Vomiting

  2003cites this paper